{"id":405,"date":"2025-11-01T06:59:06","date_gmt":"2025-11-01T06:59:06","guid":{"rendered":"https:\/\/cninmed.com\/en\/?p=405"},"modified":"2025-11-01T07:00:15","modified_gmt":"2025-11-01T07:00:15","slug":"china-bd-2025-minwei-biotech-lepu-and-sidera-bio-enters-a-1-36-billion-usd-license-for-glp-1-gip-fgf21-agonist-peptides-mwn105","status":"publish","type":"post","link":"https:\/\/cninmed.com\/en\/2025\/405.html","title":{"rendered":"[China BD 2025] Minwei Biotech (Lepu) and Sidera Bio Enters a 1 Billion USD License for GLP-1\/GIP\/FGF21  Agonist Peptides MWN105"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Announced Date: 2025-10-31 (October 31, 2025)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Asset Name: MWN105<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Licensor (Seller): Shanghai Minwei Biotech, subsidiary of Lepu Healthcare\u00a0 (China)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Licensee (Buyer): \u00a0Sidera Bio (Denmark)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Asset Modality: Peptides<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Asset Target: GLP-1\/GIP\/FGF21 Agonist<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Potential Indication:  Diabetes, Obesity<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Current Stage: Phase II in China<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Scope of Authority:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Sidera will obtain exclusive rights to develop and commercialize them globally other than Greater China (Mainland China, Hong Kong, Macau and Taiwan).\u00a0<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Payment Detail:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Minwei Biotech\u00a0will receive:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">(i) upfront and near term payment of USD$35 million,<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">(ii) receive approximately 9.99% of the equity of Sidera,<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">(iii) milestones payments of up to USD$1.01 billion.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">(iv) tiered royalties on net sales.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Link:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/static.cninfo.com.cn\/finalpage\/2025-10-31\/1224781648.PDF\">1224781648.PDF (cninfo.com.cn)<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Note:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Chinese Name of Minwei Biotech, \u6c11\u4e3a\u751f\u7269 \uff08\u4e50\u666e\uff09<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Announced Date: 2025-10-31 (October 31, 2025) Asset Name: MWN105 Licensor (Seller): Shanghai Minwei Biotech, subsidiary of &hellip; <a title=\"[China BD 2025] Minwei Biotech (Lepu) and Sidera Bio Enters a 1 Billion USD License for GLP-1\/GIP\/FGF21  Agonist Peptides MWN105\" class=\"hm-read-more\" href=\"https:\/\/cninmed.com\/en\/2025\/405.html\"><span class=\"screen-reader-text\">[China BD 2025] Minwei Biotech (Lepu) and Sidera Bio Enters a 1 Billion USD License for GLP-1\/GIP\/FGF21  Agonist Peptides MWN105<\/span>Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-405","post","type-post","status-publish","format-standard","hentry","category-china-license-out"],"_links":{"self":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/405","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/comments?post=405"}],"version-history":[{"count":2,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/405\/revisions"}],"predecessor-version":[{"id":407,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/405\/revisions\/407"}],"wp:attachment":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/media?parent=405"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/categories?post=405"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/tags?post=405"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}